Along with preclinical data indicating that long-acting GIPR agonists act in the brain to decrease body weight and food intake via GIPR signalling in inhibitory -aminobutyric acid-producing (GABAergic) neurons 5,6,7 , and by mitigating the emetic effects of GLP-1R agonism 8,9 , GIPRGLP-1R co-agonism has been established as a highly effective strategy for the management of obesity, type 2 diabetes and MASH
It is not a promise of results
GLP-1 medications mimic this hormone to slow gastric emptying, reduce hunger, stabilize blood glucose, and increase satiety, helping patients maintain a calorie deficit
Supplements use the trace element form of chromium, which is generally safe and differs from the form used for industrial purposes
202220), FITC-conjugated anti-CD11b (cat